Immunomodulatory effects of Erythropoietin in kidney transplantation

Immunomodulatory effects of Erythropoietin in kidney transplantation - IMEX

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032934

Enrollment

Registered

2023-10-30

Start date

2023-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Z94.0

Interventions

Group 1: Kidney transplant patients, kidney transplantation >12 month before enrolment, anemia with haemoglobin (Hb) <10g/dl. In this trial, we will analyse 3 sets of blood and urine samples of each e

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Kidney transplant patients, kidney transplantation >12 month before enrolment, stable immunosuppressive regimen, anemia with hemoglobin < 10g/dl

Exclusion criteria

Exclusion criteria: acute rejection, haemoglobin >11g/dl after enrolment, acute kidney injury

Design outcomes

Primary

Measure	Time frame
Increase in regulatory T cell populations in blood by 20% and reduction of effector T cells and proinflammatory macrophages in urine by 20% after 4 EPO-administrations.	—

Secondary

Measure	Time frame
- Hb increase by > 1g/dl	—

Countries

Germany

Contacts

Public ContactNina Görlich

Charité Universitätsmedizin Berlin

nina.goerlich@charite.de+49 30 450 614369

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026